NCT07182526RecruitingPhase 2
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients
Source: ClinicalTrials.gov · Last updated 19 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 29 May 2025
- Start date
- 20 Sept 2025
- Primary completion date
- 1 May 2026
- Lead sponsor
- Al-Mustansiriyah University
- NCT number
- NCT07182526
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 150
- From 20 Sept 2025 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes.
- Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction).
- Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs.
- Pregnant women.
Who the study is looking for
- • Newly diagnosed patients should be at reproductive aged from 18-40 years.
- Patients diagnosed with presence of micro polycystic ovaries at ultrasound.
- Oligomenorrhea with inter-menstrual intervals longer than 35 days.
- Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).
- Normal PRL levels.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mustansiriyah University/ College of Pharmacy Coordinator of this site? Confirm its status | Baghdad | Iraq | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.